Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Replication-Defective Human Cytomegalovirus Vaccine Elicits Humoral Immune Responses Analogous to Those with Natural Infection.
Liu Y, Freed DC, Li L, Tang A, Li F, Murray EM, Adler SP, McVoy MA, Rupp RE, Barrett D, Ye X, Zhang N, Beck K, Culp T, Das R, Song L, Vora K, Zhu H, Wang D, Espeseth AS, An Z, Musey L, Fu TM. Liu Y, et al. J Virol. 2019 Nov 13;93(23):e00747-19. doi: 10.1128/JVI.00747-19. Print 2019 Dec 1. J Virol. 2019. PMID: 31511385 Free PMC article. Clinical Trial.
Safety and Immunogenicity of V114, a 15-valent Pneumococcal Conjugate Vaccine, Compared with 13-valent Pneumococcal Conjugate Vaccine in Japanese Adults Aged ≥65 Years: Subgroup Analysis of a Randomized Phase III Trial (PNEU-AGE).
Kishino H, Sawata M, Igarashi R, Shirakawa M, Pedley A, Musey L, Platt HL, Buchwald UK. Kishino H, et al. Jpn J Infect Dis. 2022 Nov 22;75(6):575-582. doi: 10.7883/yoken.JJID.2022.060. Epub 2022 Jul 29. Jpn J Infect Dis. 2022. PMID: 35908869 Free article. Clinical Trial.
A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED).
Lupinacci R, Rupp R, Wittawatmongkol O, Jones J, Quinones J, Ulukol B, Dagan R, Richmond P, Stek JE, Romero L, Koseoglu S, Tamms G, McFetridge R, Li J, Cheon K, Musey L, Banniettis N, Bickham K; V114-029 PNEU-PED study group. Lupinacci R, et al. Vaccine. 2023 Jan 27;41(5):1142-1152. doi: 10.1016/j.vaccine.2022.12.054. Epub 2023 Jan 6. Vaccine. 2023. PMID: 36621410 Free article. Clinical Trial.
Vaccination of adults with 23-valent pneumococcal polysaccharide vaccine induces robust antibody responses against pneumococcal serotypes associated with serious clinical outcomes.
Ciprero KL, Marchese RD, Richard P, Baudin M, Sterling TM, Manoff SB, Radley D, Stek JE, Soubeyrand B, Grabenstein JD, Samson SI, Musey LK. Ciprero KL, et al. Among authors: musey lk. Hum Vaccin Immunother. 2016 Aug 2;12(8):2135-2141. doi: 10.1080/21645515.2016.1156270. Epub 2016 Mar 22. Hum Vaccin Immunother. 2016. PMID: 27002793 Free PMC article.
55 results